Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Exelon acquisition

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Jun 11, 2021 1:20pm

69 Views

Post# 33373019

RE:RE:RE:RE:Re: Exelon acquisition

Patetic? Simply reprting the Bermstein Firm upgrade of Biogem. It is a simple a zero sum game/business situation where losses of business incurred by a company/player in transactions/sales result in an equal increase in gains/sales of the opposing company player. Simple math

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December